Covid-19 roundup: As­traZeneca pub­lish­es da­ta on blood clots as­so­ci­at­ed with vac­cine; Glax­o­SmithK­line and Vir ink mAb sup­ply deal with EU

Thir­teen cas­es of throm­bo­sis with throm­bo­cy­tope­nia syn­drome in re­cip­i­ents of the As­traZeneca Covid-19 vac­cine have led to a num­ber of coun­tries paus­ing its au­tho­riza­tion. On Wednes­day, the UK drug­mak­er pub­lished cor­re­spon­dence in The Lancet show­ing that the es­ti­mat­ed rate of TTS in pa­tients who take their first dose of Vaxzevria is 8.1 per mil­lion, com­pared to 2.3 per mil­lion for those two weeks af­ter the sec­ond dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER